Evidence map›Paper›PMID 42471536›Full record

ArticleJournal of pharmacokinetics and pharmacodynamics2026

On the structural identifiability of nonlinear models of ligand binding dynamics.

Carla White, Vivi Rottschäfer, Lloyd Bridge

Abstract read
In one paragraph

Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carla WhiteSwansea University, Swansea, United Kingdom.
Vivi RottschäferLeiden University, Leiden, Netherlands.
Lloyd BridgeUniversity of the West of England, Bristol, England. lloyd.bridge@uwe.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantification of drug-cell interactions and subsequent cellular responses by using experimental data together with mathematical models of assumed binding and signalling schematics is vital to many research programmes; data fitting provides estimates for important pharmacological parameters including kinetic parameters controlling drug affinity and efficacy. Ordinary differential equation (ODE) models are a key component of many receptor theory studies used for this purpose. In using ODE simulations to fit experimental data and estimate these parameters, the theory of the identifiability properties of the system is often overlooked. Indeed, structural identifiability analysis (SIA) is often overlooked in many fields of bio-modelling. Building on recent SIA for linear ligand binding models in receptor theory, we present a new analysis of identifiability properties of nonlinear receptor theory models. We include models of ligand depletion in binding assays and ligand-induced dimerisation (LID). The classical SIA approaches of Taylor Series and similarity transformation are applied, using detailed step-by-step calculations to illustrate the complexity of the implementations. New results are obtained which show that the nonlinear ligand-depletion counterpart models of non-identifiable linear ligand excess models are globally identifiable from a single timecourse. Also, the LID model is shown to be globally identifiable if an experimental aparatus-dependent parameter is obtained. The analysis highlights issues of tractability of the methods for similar and higher-dimensional nonlinear models in receptor theory.

Indexed as

Models, BiologicalNonlinear DynamicsComputer SimulationHumansLigandsProtein BindingLigandsDifferential equationsMathematical pharmacologyReceptor theoryStructural identifiability analysis

Identifiers

PMID42471536
PMCPMC13380553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.